Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2013 Sep;72(9):824–832. doi: 10.1097/NEN.0b013e3182a0a39f

Figure 2.

Figure 2

CSF Tau cleaved by caspase 6 (TauΔCasp6) levels in groups of non-cognitively impaired (NCI), mild cognitively impaired (MCI), mild, moderate and severe Alzheimer disease (AD). (A) Linear regression of levels of CSF TauΔCasp6 vs. each subgroup of disease. ANOVA between groups p < 0.0001 and Bonferroni multiple comparison post hoc test indicates significant difference between NCI, MCI or mild AD and severe AD. (B) Linear regression (r2) between the averaged levels of TauΔCasp6 in CSF vs. the averaged global cognitive score of each subgroup. Bars indicate SD. ANOVA for the linear regression was significant [F(1,3) = 53.506, p = 0.0053].